| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892;
Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892; and
Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104
Artificial APCs (aAPCs) genetically modified to express selective costimulatory molecules provide a reproducible, cost-effective, and convenient method for polyclonal and Ag-specific expansion of human T cells for adoptive immunotherapy. Among the variety of aAPCs that have been studied, acellular beads expressing anti-CD3/anti-CD28 efficiently expand CD4+ cells, but not CD8+ T cells. Cell-based aAPCs can effectively expand cytolytic CD8+ cells, but optimal costimulatory signals have not been defined. 4-1BB, a costimulatory molecule expressed by a minority of resting CD8+ T cells, is transiently up-regulated by all CD8+ T cells following activation. We compared expansion of human cytolytic CD8+ T cells using cell-based aAPCs providing costimulation via 4-1BB vs CD28. Whereas anti-CD3/anti-CD28 aAPCs mostly expand naive cells, anti-CD3/4-1BBL aAPCs preferentially expand memory cells, resulting in superior enrichment of Ag-reactive T cells which recognize previously primed Ags and efficient expansion of electronically sorted CD8+ populations reactive toward viral or self-Ags. Using HLA-A2-Fc fusion proteins linked to 4-1BBL aAPCs, 3-log expansion of Ag-specific CD8+ CTL was induced over 14 days, whereas similar Ag-specific CD8+ T cell expansion did not occur using HLA-A2-Fc/anti-CD28 aAPCs. Furthermore, when compared with cytolytic T cells expanded using CD28 costimulation, CTL expanded using 4-1BB costimulation mediate enhanced cytolytic capacity due, in part, to NKG2D up-regulation. These results demonstrate that 4-1BB costimulation is essential for expanding memory CD8+ T cells ex vivo and is superior to CD28 costimulation for generating Ag-specific products for adoptive cell therapy.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported, in part, by the Intramural Research Program of the National Cancer Institute.
2 Address correspondence and reprint requests to Dr. Crystal L. Mackall, Immunology Section, Pediatric Oncology Branch, National Cancer Institute, Building 10-CRC, 1W-3940, 10 Center Drive, MSC 1928, Bethesda, MD 20892. E-mail address: cm35c{at}nih.gov
3 Abbreviations used in this paper: LBL, lymphoblast cell line; aAPC, artificial APC.
This article has been cited by other articles:
|
|
 |
|
  A. Di Stasi, B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. Foster, H. E. Heslop, M. K. Brenner, G. Dotti, and B. Savoldo T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood, June 18, 2009; 113(25): 6392 - 6402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Powell Jr and B. L. Levine Adoptive T-cell therapy for malignant disorders Haematologica, October 1, 2008; 93(10): 1452 - 1456. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yan, B. D. Johnson, and R. J. Orentas Induction of a VLA-2 (CD49b)-Expressing Effector T Cell Population by a Cell-Based Neuroblastoma Vaccine Expressing CD137L J. Immunol., October 1, 2008; 181(7): 4621 - 4631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Caserta, P. Alessi, J. Guarnerio, V. Basso, and A. Mondino Synthetic CD4+ T Cell-Targeted Antigen-Presenting Cells Elicit Protective Antitumor Responses Cancer Res., April 15, 2008; 68(8): 3010 - 3018. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
